Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
破解密码：了解拜玛林制药的分析师评论
9 analysts have expressed a variety of opinions on Biomarin Pharmaceutical (NASDAQ:BMRN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
过去一个季度，有9位分析师就拜玛林制药（纳斯达克:BMRN）发表了各种不同的观点，从看好到看淡不一。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他们最近评级的精简视图，显示了过去30天的不同情绪，并将其与前几个月进行比较。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $99.67, a high estimate of $115.00, and a low estimate of $72.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.2%.
分析师评估的12个月目标价格揭示了更多见解，平均目标为99.67美元，最高估价为115.00美元，最低估价为72.00美元。显而易见的是，情绪出现了负面转变，因为分析师已将平均目标价格下调了1.2%。
Investigating Analyst Ratings: An Elaborate Study
分析师评级的调查：一项详尽的研究
In examining...
通过...
登录免费看全文
登录/注册